Crossmark

Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition

Crossref DOI link: https://doi.org/10.1186/s40425-019-0698-6

Published Online: 2019-08-13

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Newton, Jared M.

Hanoteau, Aurelie

Liu, Hsuan-Chen

Gaspero, Angelina

Parikh, Falguni

Gartrell-Corrado, Robyn D.

Hart, Thomas D.

Laoui, Damya

Van Ginderachter, Jo A.

Dharmaraj, Neeraja

Spanos, William C.

Saenger, Yvonne

Young, Simon

Sikora, Andrew G.
Funding

Funding for this research was provided by:

National Institute of General Medical Sciences (T32GM088129)

National Institute of Dental and Craniofacial Research (F31DE026682)

National Institute of Dental and Craniofacial Research (DE023577)

National Institute of Dental and Craniofacial Research (U01DE028233)

National Center for Advancing Translational Sciences (KL2TR001874)
License Information

Text and Data Mining valid from 2019-08-13
More Information

Article History

Received: 16 April 2019

Accepted: 31 July 2019

First Online: 13 August 2019

Ethics approval and consent to participate

: All mice were housed and treated in accordance with Institutional Animal Care and Use Committee guidelines at Baylor College of Medicine.

: Not applicable.

: RDG-C has received travel support from PerkinElmer and has consulted on an advisory board for Northwest Biotherapeutics. AGS receives support in the form of investigational drug from Advaxis for an investigator-initiated clinical trial. AGS receives funds for clinical trial development from Tessa Therapeutics in the form of grant support.